The Impact of Artificial Intelligence Techniques and Machine Learning on Colorectal Cancer Management.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Anahita Azinfar, Negar Namvar, Ibrahim Saeed Gataa, Majid Khazaei, Seyed Mahdi Hassanian, Mohammadreza Nassir, Gordon A Ferns, Hamid Naderi, Amir Avan
{"title":"The Impact of Artificial Intelligence Techniques and Machine Learning on Colorectal Cancer Management.","authors":"Anahita Azinfar, Negar Namvar, Ibrahim Saeed Gataa, Majid Khazaei, Seyed Mahdi Hassanian, Mohammadreza Nassir, Gordon A Ferns, Hamid Naderi, Amir Avan","doi":"10.2174/0113816128377312250827213457","DOIUrl":null,"url":null,"abstract":"<p><p>Bowel cancer, known as colorectal cancer (CRC), is among the most common types of newly diagnosed cancers and a leading cause of cancer-related deaths. Despite advances in medical technology and screening programs, gaps in the detection of colorectal cancer patients persist, leading to delayed diagnoses and poorer outcomes. Therefore, new approaches using artificial intelligence-based analysis with gene panels and traditional risk factors for risk prediction and identification of cases at high risk are urgently warranted. Artificial Intelligence (AI) has emerged as a promising tool to enhance early detection and screening efficacy. Moreover, early detection is crucial for successful treatment and improved survival rates. However, conventional screening methods, such as colonoscopy and fecal occult blood tests (FOBT), have their limitations, including cost, invasiveness, and patient compliance. As a result, many individuals go undiagnosed until the disease has progressed to an advanced stage. In aggregate, the integration of AI in CRC detection holds great promise for bridging the existing gaps and improving patient outcomes. As technology continues to evolve, AI algorithms will become even more sophisticated, accurate, and scalable. Collaboration between clinicians, researchers, and AI developers is essential to harness the full potential of AI for earlier detection and better management of CRC, ultimately saving lives and reducing the global burden of disease.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128377312250827213457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Bowel cancer, known as colorectal cancer (CRC), is among the most common types of newly diagnosed cancers and a leading cause of cancer-related deaths. Despite advances in medical technology and screening programs, gaps in the detection of colorectal cancer patients persist, leading to delayed diagnoses and poorer outcomes. Therefore, new approaches using artificial intelligence-based analysis with gene panels and traditional risk factors for risk prediction and identification of cases at high risk are urgently warranted. Artificial Intelligence (AI) has emerged as a promising tool to enhance early detection and screening efficacy. Moreover, early detection is crucial for successful treatment and improved survival rates. However, conventional screening methods, such as colonoscopy and fecal occult blood tests (FOBT), have their limitations, including cost, invasiveness, and patient compliance. As a result, many individuals go undiagnosed until the disease has progressed to an advanced stage. In aggregate, the integration of AI in CRC detection holds great promise for bridging the existing gaps and improving patient outcomes. As technology continues to evolve, AI algorithms will become even more sophisticated, accurate, and scalable. Collaboration between clinicians, researchers, and AI developers is essential to harness the full potential of AI for earlier detection and better management of CRC, ultimately saving lives and reducing the global burden of disease.

人工智能技术和机器学习对结直肠癌管理的影响。
肠癌,即结直肠癌(CRC),是最常见的新诊断癌症类型之一,也是癌症相关死亡的主要原因。尽管医疗技术和筛查项目取得了进步,但对结直肠癌患者的检测仍然存在差距,导致诊断延迟和预后较差。因此,迫切需要利用基于人工智能的基因面板分析和传统风险因素进行风险预测和高风险病例识别的新方法。人工智能(AI)已成为提高早期检测和筛查效果的有前途的工具。此外,早期发现对于成功治疗和提高生存率至关重要。然而,传统的筛查方法,如结肠镜检查和粪便隐血检查(FOBT),有其局限性,包括成本、侵入性和患者依从性。因此,许多人直到疾病发展到晚期才被诊断出来。总的来说,人工智能在结直肠癌检测中的整合对于弥合现有差距和改善患者预后具有很大的希望。随着技术的不断发展,人工智能算法将变得更加复杂、准确和可扩展。临床医生、研究人员和人工智能开发人员之间的合作对于充分利用人工智能在早期发现和更好地管理结直肠癌方面的潜力,最终挽救生命并减轻全球疾病负担至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信